Healthcare / Health Information ServicesNYSE
$6.48
+0.46 (+7.64%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 33% · confianza 21%
FCF escenarios
weak_data · normalized FCF $10.4M · quality 39.7/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
39/100
D
Piotroski
7/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
20/100
SEC 0%
Sin guardar todavía.
Market Cap
$516M
P/E
N/A
•EV/EBITDA
N/A
•ROE
-34.1%
↓Gross Margin
72.1%
↑Debt/Equity
0.63
↑TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2019–2025 · 6 años de histórico normalizado
Revenue CAGR
+31.7%
FCF CAGR
—
FCF margin
5.4%
FCF / Net income
-0.46x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $239.0M · net income $-28.1M · FCF $12.9M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||
| Revenue | $239.0M | $239.0M | $204.3M | $170.5M | $142.1M | $115.9M | $79.9M | $45.7M |
| Net Income | $-28.1M | $-28.1M | $-28.3M | $-31.0M | $-49.7M | $-51.7M | $-40.4M | $-32.1M |
| EBITDA | $-10.8M | $-10.8M | $-11.2M | $-13.0M | $-31.5M | $-38.3M | $-30.1M | $-26.2M |
| EPS | -0.37 | -0.37 | -0.40 | -0.46 | -0.76 | -2.60 | -3.75 | -3.30 |
| Gross Margin | 72.1% | 72.1% | 71.4% | 68.1% | 62.5% | 57.4% | 56.9% | 59.5% |
| Operating Margin | -12.8% | -12.8% | -15.4% | -20.2% | -35.0% | -43.5% | -49.5% | -69.8% |
| Net Margin | -11.7% | -11.7% | -13.9% | -18.2% | -35.0% | -44.6% | -50.6% | -70.1% |
| Balance Sheet | ||||||||
| Debt/Equity | 0.63 | 0.63 | 0.84 | 0.75 | 0.88 | 0.09 | -0.03 | — |
| Current Ratio | 1.24 | 1.24 | — | — | — | — | — | — |
| Cash Flow | ||||||||
| Free Cash Flow | $12.9M | $12.9M | $10.4M | $6.5M | $-15.9M | $-27.7M | $-18.3M | $-24.5M |
| Returns | ||||||||
| ROE | -34.1% | -34.1% | -42.3% | -39.3% | -59.8% | -46.0% | 35.5% | 37.3% |
| Valuation | ||||||||
| P/B | 6.00 | 6.00 | 17.07 | 9.45 | 3.43 | — | — | — |
| Growth & Yield | ||||||||
| Revenue Growth | 17.0% | 17.0% | 19.9% | 19.9% | — | 45.0% | 74.7% | — |
| EPS Growth | 7.5% | 7.5% | 13.0% | 39.5% | — | 30.7% | -13.6% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-32.8%
Start / end P/E
n/dx → n/dx
EPS bridge
-0.40 → -0.37
Residual
-32.8%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.